Brief: Sosei Group Corp - Group Announces Marketing Approval For Pivlaz (Clazosentan Sodium) 150 Mg In South Korea
07/12/2023 06:34
Dec 7 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI GROUP CORP - GROUP ANNOUNCES MARKETING APPROVAL FOR PIVLAZ
(CLAZOSENTAN
SODIUM) 150 MG IN SOUTH KOREA
Source text for Eikon: ID:nTSxg7a209
Further company coverage: 4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up